Literature DB >> 6282203

Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.

G R Granneman, L T Sennello, F J Steinberg, R C Sonders.   

Abstract

This study was concerned with the single-dose, pharmacokinetics of cefmenoxime after intramuscular (i.m.) injections of 250, 500 and 1,000 mg; 1-h intravenous (i.v.) infusions of 500, 1,000, and 2,000 mg; and 5-min i.v. injections of 500, 1,000, and 2,000 mg of cefmenoxime. A total of 15 subjects were used, each receiving all three doses for one route of administration. Mean calculated peak plasma levels after the 250-, 500-, and 1,000-mg i.m. doses were 9.07, 14.68, and 26.73 micrograms/ml, respectively, occurring about 40 min after dosing. The biphasic decline in plasma levels after i.v administration was usually not apparent after i.m. dosing, because absorption of the drug from the injection depot was slower than distribution of the drug. Mean calculated peak levels from the 500-, 1,000-, and 2,000-mg i.v. doses were 22.8, 41.6, and 94.5 micrograms/ml, respectively, after the 1-h infusions and 64.1, 100.9, and 198.2 micrograms/ml, respectively after the 5-min injections. Small but statistically significant trends of decreasing alpha and increasing volume of distribution (central compartment) with increasing dose size were noted; however, this distribution phenomenon was self-compensating, resulting in no overall effect on plasma clearance. For practical purposes, the pharmacokinetics were linear. The mean 0- to 24-h urinary recoveries of cefmenoxime after the i.m. injections, i.v. infusions, and i.v. injections were 72.1, 67.5, and 74.5% respectively. Overall, the pharmacokinetics of cefmenoxime were best described by a two-compartment open model with a beta-phase half life of 0.91 h. Plasma clearance of the drug was dosage level and route independent, averaging 254 ml/min; thus, there was an excellent linear relationship between the area under the plasma level curve and the dose. The results of this study indicated that most of the drug is removed by renal mechanisms, with tubular secretion predominating.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282203      PMCID: PMC181842          DOI: 10.1128/AAC.21.1.141

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

3.  New cephalosporin derivatives with high antibacterial activities.

Authors:  M Ochiai; O Aki; A Morimoto; T Okada; Y Matsushita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1977-11       Impact factor: 1.645

4.  Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kondo; M Kida; M Nakao; T Iwahi; T Nishi; Y Noji; M Takeuchi; Y Nozaki
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

5.  Antimicrobial activity of cefmenoxime (SCE-1365).

Authors:  J M Stamm; R L Girolami; N L Shipkowitz; R R Bower
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  5 in total
  12 in total

1.  Pharmacokinetics and metabolism of an intravenously administered penem (Sch 34343) in humans.

Authors:  C C Lin; J Lim; E Radwanski; H K Kim; A Marco; A Lapiguera; C DiGiore; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

2.  Determination of cefmenoxime in human body fluids by high-performance liquid chromatography.

Authors:  K Borner; E Borner; H Lode; A Peters
Journal:  Eur J Clin Microbiol       Date:  1983-02       Impact factor: 3.267

3.  Cefodizime penetration into skin suction blister fluid following a single intravenous dose.

Authors:  M Schäfer-Korting; H C Korting; L Maass; N Klesel; H G Grigoleit; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

5.  Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.

Authors:  B Pangon; V Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Clinical efficacy and safety of cefmenoxime in children.

Authors:  G F Tansino; M R Hammerschlag; B L Congeni; P A Cox; B Doraiswamy; L duBouchet
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

7.  Metabolism of [14C]Cefmenoxime in normal subjects after intramuscular administration.

Authors:  J M Machinist; B A Bopp; D Quinn
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.

Authors:  J G Gambertoglio; D P Alexander; S L Barriere
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

9.  Cefmenoxime pharmacokinetics in patients with renal insufficiency.

Authors:  R E Polk; D A Sica; T M Kerkering; B J Kline; P M Patterson; J W Baggett
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

10.  Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; R E Polk; T M Kerkering; P Patterson; J Baggett
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.